<DOC>
	<DOCNO>NCT02516085</DOCNO>
	<brief_summary>The purpose study show intake L-arginine metformin improve muscle function delay disease progression patient Duchenne 's muscular dystrophy .</brief_summary>
	<brief_title>Improved Muscle Function Duchenne Muscular Dystrophy Through L-Arginine Metformin</brief_title>
	<detailed_description>This investigator-initiated , open-label , single-center , proof-of-concept-study . The study medication consist L-arginine metformin . The duration study 16 week comprehend one screen four study visit .</detailed_description>
	<mesh_term>Muscular Dystrophies</mesh_term>
	<mesh_term>Muscular Dystrophy , Duchenne</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Molecular diagnosis DMD Patients 7 10 year age time screen Ambulant Previous ( 3 month less ) concomitant participation another therapeutic trial Use Larginine , Lcitrulline metformin within last 3 month Known individual hypersensitivity Lcitrulline metformin Other chronic disease clinical relevant limitation renal , liver , heart function accord discretion investigator</criteria>
	<gender>All</gender>
	<minimum_age>7 Years</minimum_age>
	<maximum_age>10 Years</maximum_age>
	<verification_date>August 2015</verification_date>
</DOC>